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Nitric oxide switches on glycolysis through the AMP
protein kinase and 6-phosphofructo-2-kinase
pathway
Angeles Almeida1, Salvador Moncada2,4 and Juan P. Bolaños3
After inhibition of cytochrome c oxidase by nitric oxide1–3,
astrocytes maintain energy production by upregulating
glycolysis4,5 — a response which does not seem to be
available to neurons. Here, we show that in astrocytes, after
inhibition of respiration by nitric oxide, there is a rapid,
cyclic GMP-independent increase in the activity of 6-
phosphofructo-1-kinase (PFK1), a master regulator of
glycolysis6, and an increase in the concentration of its most
powerful positive allosteric activator7, fructose-2,6-
bisphosphate (F2,6P2). In neurons, nitric oxide failed to
alter F2,6P2 concentration or PFK1 activity. This failure
could be accounted for by the much lower amount of 6-
phosphofructo-2-kinase (PFK2, the enzyme responsible for
F2,6P2 biosynthesis8) in neurons. Indeed, full activation of
neuronal PFK1 was achieved by adding cytosol from nitric
oxide-treated astrocytes. Furthermore, using the small
interfering RNA (siRNA) strategy9, we demonstrated that the
rapid activation of glycolysis by nitric oxide is dependent on
phosphorylation of the energy charge-sensitive AMP-
activated protein kinase, resulting in activation of PFK2 and
protection of cells from apoptosis. Thus the virtual absence
of PFK2 in neurons may explain their extreme sensitivity to
energy depletion and degeneration4,5,10.
Recently, we observed that inhibition of respiration by nitric oxide
results in differing responses in astrocytes and neurons5. This con-
sists of a rapid up-regulation of glycolysis in astrocytes, which does
not occur in neurons. We suggested that this difference may under-
lie the different susceptibility of the two types of cells to injurious
stimuli, and have now investigated the mechanisms involved in the
activation of the glycolytic pathway by nitric oxide in these cells.
Initially, we investigated whether endogenously-generated nitric
oxide could affect glycolysis in the way that we previously observed
using exogenous nitric oxide . The glycolytic response was activated
both in astrocytes transfected with inducible nitric oxide synthase
(iNOS) and in lipopolysaccharide-interferon-γ (LPS-IFN-γ)-
treated astrocytes from neuronal NOS knockout (nNOS−/−) mice
(Fig. 1a). In contrast, no glycolytic activation was observed in
either LPS-IFN-γ -treated astrocytes from iNOS−/− mice (Fig. 1a)
or in neurons after activation of nNOS with glutamate (Fig. 1b).
When both cell types were exposed to an equal amount of nitric
oxide (1.4 µM nitric oxide, released from 0.5 mM DETA–NO, the
lowest concentration that maximally inhibits respiration in each
cell type5) glycolysis was upregulated in astrocytes but not in neu-
rons (Fig. 1c). Thus the two cell types respond to endogenous
nitric oxide in the same way as they do to exogenous nitric oxide.
For this reason we used exogenously applied nitric oxide to investi-
gate the steps involved in the activation of the glycolytic pathway by
nitric oxide.
Treatment with 1.4 µM nitric oxide resulted in a time-dependent
decrease in fructose-6-phosphate (F6P) and increase in fructose-
1,6-biphosphate (F1,6P2) concentrations (the substrate and prod-
uct of PFK1, respectively) in astrocytes, but not in neurons (Fig.
1d). The specific PFK1 activity was found to be approximately
fourfold higher in astrocytes (Fig. 1e). Furthermore, using specific
polyclonal antibodies raised against PFK1 isoforms, muscle (M),
liver (L) and brain (C), we showed that, although the constitutive
protein expression of PFK1.M and PFK1.L was similar in both cell
types, the expression of PFK1.C was approximately fourfold greater
in astrocytes than in neurons (Fig. 1e). This suggests that this latter
isoform has a function in the different responses of the two cell
types to nitric oxide.
The time course that we observed for PFK1 activation is too
short to involve changes in protein expression. Furthermore,
allosteric regulation of PFK1.C by ATP and AMP has been demon-
strated in other cells11. Because of this, we decided to investigate
the allosteric-dependent changes in PFK1 function by measuring
the relative PFK1 activity (v/Vmax)
12 in astrocytes and neurons in
the presence of supernatant freshly obtained from untreated or
nitric oxide-treated cells. Our results demonstrated that super-
natant from untreated astrocytes, but not neurons, contained
metabolite(s) that stimulated relative PFK1 activity in both astro-
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cytes and neurons to a similar extent (Fig. 2a). In addition, nitric
oxide triggered the accumulation in astrocytes, but not in neurons,
of a stable regulatory metabolite(s) able to activate fully PFK1 to
v/Vmax values up to approximately 0.85–0.95 in both cell types (Fig.
2a). These results suggest that factor(s) besides PFK1 are responsi-
ble for the difference in glycolytic response to nitric oxide in astro-
cytes and neurons. As F2,6P2 has been reported as the most
powerful allosteric activator of PFK1(refs 13–15), we decided to
investigate whether it was involved in the activation of PFK1 by
nitric oxide. Nitric oxide triggered a rapid (approximately 5 min)
and time-dependent (up to 60 min) accumulation of F2,6P2 in
astrocytes (Fig. 2b). Neuronal basal F2,6P2 concentrations were
approximately 4.5-fold lower, and were not affected by nitric oxide
(Fig. 2b).
The synthesis and degradation of F2,6P2 is catalysed by the
homodimeric enzyme 6-phosphofructo-2-kinase–fructose-2,6-bis-
phosphatase (PFK2). This bifunctional enzyme controls the intra-
cellular concentrations of F2,6P2 through regulation of gene
expression and phosphorylation states, and hence regulates the gly-
colytic rate under multiple pathophysiological conditions6,14,16.
PFK2 is expressed in a number of tissue-specific isoforms
(PFK2.1–4) generated by alternative splicing from four genes
(PFKFB 1–4), and these differ in their regulatory properties and
kinase–bisphosphatase activity ratio14,15,17. Reverse transcription
polymerase chain reaction (RT–PCR) analysis of these isoforms
demonstrated that astrocytes mainly expressed PFK2.3 and
PFK2.4, whereas PFK2.2 was only marginally expressed and
expression of PFK2.1 was negligible (Fig. 2c). Of the PFK2 iso-
forms, the highest kinase–bisphosphatase activity ratio — thus
generating more F2,6P2 — is exhibited by PFK2.3, the ubiquitous
PFK2 isoform that is present in placenta, brain and tumour
cells17,18. This resulted in the suggestion that F2,6P2-mediated
allosteric activation of PFK1 may be responsible for the higher gly-
colytic rate demonstrated in those tissues in which PFK2.3 is
expressed17,19–22. In addition, it has been suggested that the high
F2,6P2 concentration found in whole brain tissue has a permissive
function in overcoming inhibition of PFK1 by ATP and maintain-
ing this enzyme in an activated state22. Our results demonstrate
that such permissive PFK1 activation in the brain would be con-
fined to the astrocytes, where there is a greater expression of
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Figure 1 Nitric oxide activates glycolysis through PFK1. (a) Nitric oxide,
formed by iNOS-transfected astrocytes (pcDNA5iNOS) increased release of
lactate (60 min). Incubation of astrocytes from nNOS−/− mice with LPS–IFN-
γ for 14 h increased the release of lactate (expressed as the difference
between LPS–IFN-γ-treated and untreated cells) and nitrite, whereas these
effects did not occur in astrocytes from iNOS−/− mice. Lactate and nitrite
concentrations in astrocytes from control mice demonstrated similar results
to those obtained from nNOS−/− mice (data not shown). Lactate values in
astrocytes from untreated nNOS−/− and iNOS−/−mice at 14 h were 7.78 ±
0.11 and 7.64 ± 0.29 µmol/106 cells, respectively. (b) Activation of nNOS
with glutamate (100 µM, 15 min) failed to alter formation of lactate in
neurons. (c) Exposure of both cell types to equal amounts of nitric oxide
(1.4 µM) for 60 min increased lactate release in astrocytes, but not in
neurons. (d) Nitric oxide increased the F1,6P2/F6P ratio in astrocytes, but
not in neurons, indicating activation of PFK1. (e) PFK1-specific activity is
higher in astrocytes than in neurons. Isoform PFK1.C protein was
predominant in astrocytes when compared with neurons, whereas isoforms
PFK1.L or PFK1.M were similarly expressed in both cell types. * refers to p
< 0.05 versus corresponding control; # refers to p < 0.05 versus
corresponding values from iNOS−/−.
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PFK2.3 (Fig. 2d) and more F2,6P2 (Fig. 2b) than in neurons.
Treatment with nitric oxide (30 min) did not affect PFK2.3 protein
content in either cell type (data not shown), suggesting that nitric
oxide-mediated F2,6P2 increase was a consequence of allosteric
PFK2.3 activation.
Next, we investigated whether blockade of PFK2.3 affected the
glycolytic response of astrocytes to nitric oxide. As PFK2.3 mRNA
contains an AU-rich instability element in its 3′-untranslated
region20, we used the RNA interference approach to block PFK2.3
protein expression. A double-stranded small interfering RNA-like
structure (siRNA) specifically targeted against PFK.2.3 isoform was
expressed in primary astrocytes using a pSuper mammalian expres-
sion vector9. Treatment of astrocytes with siRNA targeted against
PFK2.3 (pSuperPFK2.3) for 48 h severely depleted PFK2.3 protein
levels when compared with treatment of cells with the vector alone
(pSuper; Fig. 2e). Treatment with nitric oxide increased the release
of lactate and intracellular F2,6P2 concentrations in pSuper cells
(Fig. 2f), a response which was abolished in pSuperPFK2.3 cells.
Furthermore, treatment with oligomycin, an inhibitor of the
F0F1–ATPase, increased the concentrations of lactate and F2,6P2
under identical conditions; these effects were fully prevented by
silencing of PFK2.3 (Fig. 2f). These results strongly suggest that
PFK2.3 is essential for nitric oxide-triggered PFK1 upregulation.
The possible involvement of the soluble guanylyl cyclase in the
nitric oxide-mediated stimulation of PFK1 and glycolysis in astro-
cytes was then investigated. ODQ (1H-(1,2,4) oxadiazolol-[4,3-α]-
quinoxaline-1-one), which prevented NO-mediated elevation of
cyclic GMP, had no effect on the nitric oxide-dependent enhance-
ment of the activities of PFK1 and PFK2 or the release of lactate
(Fig. 3a). Furthermore, BAY41–2272, which increased cyclic GMP
concentrations, had no effect on these parameters either (Fig. 3a).
These results suggest that nitric oxide-mediated glycolytic activa-
tion in astrocytes is a cyclic GMP-independent phenomenon.
However, the inhibitors of mitochondrial respiration, potassium
cyanide and oligomycin increased the activities of PFK1 and PFK2
and the release of lactate (Fig. 3a). These results, together with our
observation that PFK2.3 silencing prevented oligomycin-mediated
enhancement of lactate release and F2,6P2 concentrations (Fig. 2e),
clearly indicate that nitric oxide-mediated activation of glycolysis
in astrocytes is a consequence of mitochondrial inhibition.
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Figure 2 Nitric oxide triggers allosteric PFK1 activation through PFK2. (a)
Cytosol from astrocytes directly activated neuronal PFK1. This ability to
activate PFK1 was enhanced by treatment of the astrocytes with nitric oxide
for 30 min, however, neuronal cytosol was unable to mimic this action. (b)
Nitric oxide increased F2,6P2 concentrations in astrocytes, but not in
neurons. (c) RT-PCR analysis of PFK2 isoforms in astrocytes demonstrates
higher expression of PFK2.3 and PFK2.4 than PFK2.2 or PFK2.1. (d)
PFK2.3 protein was expressed in astrocytes, but was undetectable in
neurons. (e) Transfection of astrocytes with a plasmid construct expressing a
siRNA targeted against PFK2.3 (pSuperPFK2.3) for 48 h effectively
reduced the concentration of PFK2.3 protein when compared with cells
transfected with the vector alone (pSuper). (f) PFK2.3-deficient astrocytes
(pSuperPFK2.3) but not control astrocytes (pSuper) failed to increase the
release of lactate or the intracellular concentrations of F2,6P2 after
treatment with nitric oxide or oligomycin (5 µM). * refers to p < 0.05 versus
corresponding control.
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To investigate this possibility further, we focused on AMP-acti-
vated protein kinase (AMPK), which is potently activated after
phosphorylation at Thr 172 by the upstream AMPK kinase when
the AMP/ATP ratios are elevated23. Once activated, AMPK switches
on catabolic pathways, both acutely by phosphorylation of meta-
bolic enzymes and chronically by gene expression, and switches off
many ATP-consuming processes23. Recently, it was reported that
AMPK mediates PFK2–Ser 466 phosphorylation, and enzyme acti-
vation in the heart in response to ischaemia24. We previously
reported that inhibition of respiration in astrocytes by nitric oxide
inhibits ATP concentrations by approximately 25% (ref. 5). We
therefore investigated whether inhibition of respiration would be
sufficient to activate AMPK, and thus switch on glycolysis. As with
nitric oxide, potassium cyanide rapidly (within 10 min) triggered
AMPK–α–Thr 172 phosphorylation, as did oligomycin, a well-
known activator of AMPK (Fig. 3b). To confirm this, we con-
structed a pSuper vector carrying a siRNA against AMPK
(pSuperAMPK). Transfection of astrocytes or HEK293T cells for 72
h with pSuperAMPK efficiently decreased AMPK protein and ren-
dered the cells unable to respond to nitric oxide or oligomycin by
increasing the release of lactate or F2,6P2 concentrations (Fig. 4a;
see also Supplementary Information, Fig. S1). Furthermore, the
increases in lactate (Figs 1a, 4b) and in F2,6P2 concentrations (Fig.
4b) were observed in LPS–IFN-γ-treated astrocytes from nNOS−/−,
but not in those from iNOS−/−mice. Such effects were prevented by
transfection with either pSuperAMPK or pSuperPFK2.3 (Fig. 4b),
strongly suggesting the involvement of the AMPK–PFK2 pathway
in activation of glycolysis by endogenous nitric oxide in astrocytes.
To investigate whether the AMPK–PFK2 pathway is involved in cel-
lular resistance against nitric oxide-mediated cell death5, apoptotic
cells (annexin V+-PI−) were quantified by flow cytometry after 60
min treatment with nitric oxide or oligomycin. Reducing the levels
of AMPK (pSuperAMPK) or PFK2.3 (pSuperPFK2.3) resulted in a
significant increase in apoptosis in nitric oxide- and in oligomycin-
treated cells (Fig. 4c; see Supplementary Information, Fig. S1). Our
results therefore indicate that, in astrocytes, nitric oxide is able to
upregulate glycolysis rapidly through a pathway that involves the
activation of PFK2.3 by AMPK. The failure of neurons to operate
such a mechanism may be a key contributing factor in their suscep-
tibility to neurodegeneration.
METHODS
Cell cultures. Cortical astrocytes or neurons in primary culture were pre-
pared from neonatal (P0) or fetal (E16) Wistar rats, respectively. Cortical
astrocytes were also obtained from P0 mice lacking either nNOS (nNOS−/−)
or iNOS (iNOS−/−) (The Jackson Laboratories, Bar Harbor, ME. Strain
names B6.129S4 and B6.129P2, respectively donated by J.R. Alonso,
University of Salamanca, Salamanca, Spain and by L. Boscá, Centro
Nacional de Investigaciones Cardiovasculares (CNIC; Madrid, Spain).
Control mice were C57BL/6J 000664 (bred at the University of Salamanca,
Spain). Cells were seeded (2.5 × 105 cells/cm2) in DMEM (Sigma, Madrid,
Spain) supplemented with 10% (v/v) foetal calf serum (FCS; Roche
Diagnostics, Heidelberg, Germany) and incubated at 37 °C under a humid-
ified 5% carbon dioxide-containing atmosphere. For neuronal cultures, 48
h after plating, the medium was replaced with DMEM supplemented with
5% horse serum (Sigma) and with 20 mM D-glucose, and on day four, cyto-
sine arabinoside (10 µM) was added to prevent non-neuronal proliferation.
Cells were used by day eight (neurons) or twelve (astrocytes). Enrichment
was approximately 99% (neurofilament) or approximately 85% (glial–fib-
rillary acidic protein) in neurons or astrocytes, respectively. Most other cells
in astrocytic cultures were microglia and progenitor cells. HEK293T cells
were incubated in DMEM containing 10% FCS and seeded at 105 cells/cm2
24 h before the experiments.
Design and expression of PFK2 and AMPK siRNAs. PFK2.3 or AMPK disrup-
tion was achieved by RNA interference using a vector-based siRNA approach9.
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Figure 3 Activation of glycolysis by nitric oxide is cyclic GMP-independent
and may involve AMPK phosphorylation. (a) Cyclic GMP was elevated in
astrocytes by nitric oxide or BAY41–2272 (BAY, 2 µM). Nitric oxide-mediated
increases in F1,6P2/F6P ratio, lactate released or F2,6P2 concentrations
were not prevented by inhibition of soluble guanylyl cyclase with ODQ (1 µM),
which prevented elevation of cyclic GMP. Elevation of cyclic GMP by BAY was
not accompanied by changes in the F1,6P2/F6P ratio, lactate released or
F2,6P2 concentrations. (b) Nitric oxide, potassium cyanide (4 mM) or
oligomycin (5 µM) triggered AMPK-α-Thr 172 phosphorylation in astrocytes
after 10 min. * refers to p < 0.05 versus corresponding control.
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The target sequences were 5′-AAAGCCTCGCATCAACAGC-3′ (nt 1908–1926,
accession number NM 057135) for the placental PFK2 isoform (PFK2.3), and
5′-GAATCCTGTGACAAGCACA-3′ (nt 1311–1329, accession number NM
019142) for AMPK-α1 catalytic subunit. Both sequences were confirmed for
specificity. The forward and reverse synthetic 64-nt oligonucleotides (Isogen
Life Technologies, Maarsen, The Netherlands) were designed, annealed and
inserted into the BglII/HindIII sites of a green fluorescent protein (GFP) cDNA
-carrying pSuper mammalian expression vector (Oligoengine, Seattle, WA)
according to the manufacturer’s instructions. These constructions express a 
19-base pair, 9-nt stem-loop structure (small hairpin RNA) specifically tar-
geted against PFK2.3 or AMPK-αmRNAs. Transfections of primary astrocytes
or HEK293T cells were performed with the plasmid constructions
(pSuperPFK2.3 or pSuperAMPK) or with the vector alone (pSuper) for 48–72
h using Lipofectamine 2000 (Invitrogen, Madrid, Spain) according to the
manufacturer’s instructions. The efficiency of transfection was approximately
60% (astrocytes) or approximately 95% (HEK293T), as assessed by quantita-
tion of fluorescent cells, and the efficacy of siRNA procedure was confirmed by
western blotting.
Incubations of cells with nitric oxide. To achieve nitric oxide production by
astrocytes, the cells were transfected (Lipofectamine 2000) with the full-
length iNOS cDNA, inserted in the pcDNA5 mammalian expression vector
(pcDNA5iNOS construction, provided by J. Mateo, CNIC) in the presence
of the nitric oxide synthase inhibitor S-ethylthiourea (0.5 mM). After 24 h, the
inhibitor was removed and nitric oxide biosynthesis was confirmed by deter-
mination of nitrite released by the cells in buffered Hanks’ solution (5.26 mM
potassium chloride, 0.43 mM KH2PO4, 132.4 mM sodium chloride, 4.09 mM
NaHCO3, 0.33 mM Na2HPO4, 20 mM glucose, 2 mM calcium chloride and 20
mM HEPES at pH 7.4). To promote endogenous nitric oxide biosynthesis in
astrocytes, these cells were incubated with LPS (0.1–5 µg ml−1) plus IFN- γ
(10–500 U ml−1) for 14 h. To obtain endogenous nitric oxide production in
neurons, the cells were treated with glutamate (100 µM for 15 min) in buffered
Hanks’ solution, and nitric oxide formation was confirmed by cyclic GMP
determination. To expose the cells to equal amounts of nitric oxide, they were
incubated in buffered Hanks’ solution containing DETA-NO (Alexis
Corporation, San Diego, CA) at 0.5 mM, the concentration seen to continu-
ously release approximately 1.4 µM of nitric oxide for about 18 h at 37 °C, as
measured by a nitric oxide-sensitive electrode (World Precision Instruments,
Sarasota, FL). To ensure immediate exposure of the cells to nitric oxide, all
DETA-NO-containing solutions were always pre-incubated in buffered Hanks’
solution at 37 °C for 20 min before addition to the cells. Under these condi-
tions, nitric oxide inhibited mitochondrial respiration by 85–90% (ref. 5). As
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Figure 4 AMPK mediates nitric oxide-dependent glycolytic activation and
prevents apoptotic cell death. (a) Transfection of astrocytes with a
plasmid construction expressing a siRNA targeted against AMPK-α
(pSuperAMPK) efficiently reduced AMPK-α protein when compared with
cells transfected with the vector alone (pSuper). Treatment of AMPK-α-
deficient astrocytes (pSuperAMPK) with nitric oxide or oligomycin (5 µM)
prevented the accumulation of lactate and of intracellular F2,6P2
concentrations that was observed with the vector alone (pSuper). (b)
Incubation for 14 h with LPS (1 µg ml−1) plus IFN-γ (100 U ml−1)
increased lactate and F2,6P2 concentrations in astrocytes from nNOS−/−,
but not in those from iNOS−/− mice. Transfection of nNOS−/− mice
astrocytes with pSuperAMPK or pSuperPFK2.3 prevented LPS–IFN-γ-
mediated enhancement of lactate and F2,6P2 concentrations when
compared with cells treated with vector alone (pSuper). Incubation of
nNOS−/—mice astrocytes with LPS–IFN-γ after plasmid vector
transfection increased nitrite concentrations to values similar to those
depicted in Figure 1a (data not shown). (c) Treatment with nitric oxide or
oligomycin (5 µM) resulted in increased apoptosis (annexin V+-PI−) of
AMPK-α- or PFK2.3-deficient astrocytes, but not their controls. * refers
to p < 0.05 versus corresponding control.
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controls, incubations were performed in the presence of a degraded DETA-
NO solution (37 °C for 48 h).
Determination of specific activity and allosteric regulation of PFK1.
Approximately 107 cells were sonicated in 0.2 ml of 50 mM Tris phosphate
buffer (at pH 8.0) containing 10 mM dithiothreitol, 1 mM EDTA, 1 mM
EGTA, 0.02% phenylmethylsulfonyl fluoride, 2 mM benzamidine and 10 U
ml−1 aprotinin, and centrifuged (20,000g for 30 min). PFK1-specific activity
was determined in the supernatants by monitoring the rate of F1,6P2 for-
mation from F6P and ATP25. To determine the effect of cytosolic regulatory
metabolites on PFK1 activity (relative PFK1 activity), supernatants were
deproteinized by 10 kDa cut-off filtration (Millipore, Madrid, Spain).
Eluates were then immediately used as the metabolite source for PFK1 activ-
ity determination, in unfiltered supernatants, in the absence of F6P and
ATP12. Relative PFK1 activity was expressed as the ratio of PFK1 activity
obtained in the presence of equivalent amounts of cytosolic regulatory
metabolites obtained from untreated or nitric oxide-treated cells (30 min)
versus maximum PFK1 activity (measured in the presence of F6P and ATP,
Vmax)
12.
Metabolite determinations. F6P and F1,6P2 concentrations were measured
in neutralized perchloric extracts obtained from approximately 3 × 107
cells26,27. Lactate concentrations were determined in the media26. For
F2,6P2 determinations, cells extracts were lysed, as described
12, in 0.1 N
sodium hydroxide and centrifuged (20,000g for 20 min). An aliquot of the
homogenate was used for protein determination28 and the remaining sam-
ple was heated at 80 °C (5 min), centrifuged (20,000g for 20 min) and the
resulting supernatant used for the determination of F2,6P2 concentra-
tions27. Cyclic GMP was measured by radioimmunoassay (Amersham
Biosciences, Buckinghamshire, UK) and nitrite was measured colorimetri-
cally by the Griess reaction.
Western blotting analysis. Aliquots (100 µg of protein) of cell lysates (in 2%
sodium dodecylsulfate, 2 mM EDTA, 2 mM EGTA, 5 mM Tris, 100 µM
phenylmethylsulfonyl fluoride, 50 µg ml−1 anti-papain, 50 µg ml−1 pep-
statin, 50 µg ml−1 amastatin, 50 µg ml−1 leupeptine, 50 µg ml−1 bestatin and
50 µg ml−1 soybean trypsin inhibitor) were centrifuged (14,000g, 10 min)
and electrophoresed in a SDS/8% acrylamide gel (MiniProtean®, Bio-Rad )
using a BenchMarkTM prestained protein ladder (Isogen Life Technologies).
The resolved proteins were transferred electrophoretically to nitrocellulose
membranes, which were blocked in 5% (w/v) low-fat milk in 20 mM Tris,
500 mM sodium chloride, 0.1% (w/v) Tween-20 (at pH 7.5) for 1 h, and
further incubated with anti-PFK1.L, anti-PFK1.M or anti-PFK1.C (pro-
vided by Dr. Emilio Fernández, Universidad de Salamanca, Spain), anti-
PFK2.3 (gift from Dr. R. Bartrons, University of Barcelona, Barcelona,
Spain), anti-phospho-AMPK-α–Thr 172 or anti-AMPK-α (Cell Signalling
Technology, Beverly, MA). Horsereadish peroxidase (HRP) antirabbit IgG-
treated membranes (Santa Cruz Biotechnology, Santa Cruz, CA) were devel-
oped by luminol-chemiluminescence.
RT-PCR analysis. Total RNA was purified from astrocytes using a commer-
cially available kit (Sigma). PFK2 mRNA isoform expression was analysed
by 4.5% agarose electrophoresis in DNA-free RNA aliquots (1 µg) after RT-
PCR (50 min at 48°C for reverse transcription; 35 cycles of 30 s at 95 °C,
30 s at 55 °C and 30 s at 72 °C; 10 min at 72 °C) (Applied Biosystems,
Madrid, Spain) using the following forward and reverse oligonucleotides,
respectively: 5′-CTCACCCCCTTCCTCCTGTAG-3′ and 5′-GGC-
CATAGCCAGAGTCTGCTT-3′ for PFK2.1 (accession number NM 012621;
nt 1649–1714); 5′-GGATGGCAAGTTGG-GTTTTTAG-3′ and 5′-ACAGAA-
GAACCAAGTCTATGACTCATG-3′ for PFK2.2 (accession number NM
080477; nt 1914–1992); 5′-CCCCGAGCCCACCAAA-3′ and 5′-
CAGAAGTGGAAGCCACATGCT-3′ for PFK2.3 (accession number
NM057135; nt 1893–1954); 5′-CACTCCAGGCCACTTCTTCCT-3′ and 5′-
CACTCCAGGCCACTTCTTCCT-3′ for PFK2.4 (accession number NM
019333; nt 1477–1543). In no case was a band detected by PCR without
reverse transcription.
Flow cytometric analysis of apoptosis. Alexa Fluor 488-conjugated annexin
V-propidium iodide (PI)-based Vybrant Apoptosis Assay kit (Molecular
Probes, Eugene, OR) was used, and cells analysed with a FACScalibur flow
cytometer (15 mW argon ion laser tuned at 488 nm; CellQuest software,
Becton-Dickinson Biosciences, Erembodegen, Belgium). Annexin V-stained
cells that were PI-negative (annexin V+-PI−) were considered to be apop-
totic.
Statistical analyses. Significances were assessed by ANOVA followed by the
least significant difference multiple range test. The results are the mean ±
SEM values for at least three different culture preparations.
Note: Supplementary Information is available on the Nature Cell Biology website.
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Fig. S1. AMPK- or PFK-2-mediated F2,6P2 accumulation is involved in NO-
dependent glycolytic activation, and protects HEK293T cells from
apoptosis. (a) Transfection of HEK293T cells with plasmid constructs
expressing siRNA targeted against AMPK-α (pSuperAMPK) or PFK2.3
(pSuperPFK2) for 48 h effectively reduced the proteins AMPK-α or PFK2.3
when compared with cells transfected with the vector alone (pSuper). (b)
HEK293T cells deficient in AMPK-α or PFK2.3 failed to accumulate F2,6P2
in response to NO or to oligomycin (OLIG, 5 µM). (c) Treatment with NO or
oligomycin (OLIG 5µM) led to increased apoptosis (annexin V+-PI-) of
AMPK-α- or PFK2.3-deficient HEK293T cells, but not their controls.
*p<0.05 versus corresponding control.
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